John D. Lewis

John Lewis is the Bird Dogs Chair in Translational Oncology at the University of Alberta, Edmonton, Alberta. In addition to his academic work, Dr. Lewis is the co-founder of Innovascreen Inc., a successful preclinical CRO in operation since 2005, and the founder and CEO of Entos Pharmaceuticals Inc., a clinical-stage biotechnology company developing genetic medicines, incorporated in 2007. His research involves cancer diagnostics, non-invasive molecular imaging, and targeting of angiogenesis and metastasis using multivalent nanoparticles. He trained at The Scripps Research Institute in La Jolla, CA where he developed targeted molecular imaging technologies. John Lewis earned a Ph.D. in biochemistry from the University of Victoria.